It's true that we've had recalls of products based on nitrosamines. Nitrosamines, as you know, are impurities that can happen from manufacturing. We have seen more products test positive for nitrosamines over the past few years. It may be that we've also had better technology for detecting them. We're working internationally with our partners, specifically the European Medicines Agency, to share information on how to improve the manufacturing process. We're also being very clear about what limits are acceptable, because certain nitrosamine levels in the products are acceptable, while others may potentially cause longer-term problems.
Certainly, any time there is a recall, we always weigh the risks and the benefits of that, and we are very cognizant of the fact that people are depending on these medications and it may not be that easy to switch. This is definitely not just a Canadian issue but a global issue, and international collaboration is ongoing on getting to the bottom of the manufacturing processes that may give rise to these higher levels of impurities.